Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.ENVB · Entity 8193 | President and COO | January 25, 2023 | January 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date January 25, 2023 · Filed January 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,346 |
Reported balance
After 2023-01-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-25 · Grant · Acquired 10,000 · Balance 48,346 F1: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance. F2: Includes 38,346 restricted stock units previously reported on Table II. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance.
F2: Includes 38,346 restricted stock units previously reported on Table II.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2023 Filed Jan 27, 2023 22:05 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-002800 · ownership.xml · nonDerivative · entry 1 Kanubaddi Avani · CIK 0001838498 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,346 F1 · shares: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance. F2 · balance_after: Includes 38,346 restricted stock units previously reported on Table II. Read SEC document |
| January 19, 2022 Filed Jan 25, 2022 21:53 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantRestricted Stock Units · Derivative | 1,127,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-002201 · ownership.xml · derivative · entry 1 Kanubaddi Avani · CIK 0001838498 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,787 Underlying: Common Stock · 1,127,787 shares Expires not disclosed F1 · security: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. F2 · derivative.exercise_price: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. F2 · derivative.exercise_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. F2 · derivative.expiration_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 00:24 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantRestricted Stock Units · Derivative | 789,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-004172 · ownership.xml · derivative · entry 1 Kanubaddi Avani · CIK 0001838498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,484 Underlying: Common Stock · 789,484 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan (the "Plan"). For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock upon termination of employment with or services to the Company or in connection with a change of control, as set forth in the reporting person's restricted stock unit award agreement. F2 · derivative.exercise_date: One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan. F2 · derivative.expiration_date: One-third (1/3rd) of the restricted stock units vested as of December 30, 2020, and the remaining two-thirds (2/3rds) of the restricted stock units shall vest in three equal tranches, with the vesting of each tranche based on the achievement of a performance milestone established by the compensation committee of the board of directors of the Company for such tranche and as set forth in the reporting person's restricted stock unit award agreement, provided the reporting person is employed by or providing services to the Company through the applicable vesting date, and subject to certain restrictions and conditions set forth in the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.